The University of Kentucky Public Relations & Strategic Communications Office provides a weekly health column available for use and reprint by news media. This week's column is by Dr. Larry Goldstein, chair of the Department of Neurology, Co-director of the Kentucky Neuroscience Institute, and Interim director of the UK-Norton Stroke Care Network.
LEXINGTON, Ky. (Nov. 9, 2020) — More than seven months have passed since the onset of the COVID-19 pandemic in the United States, and hundreds of reports have been published related to various aspects of the disease caused by the SARS-Co-V2. Despite knowing the virus’ genetic composition, its primary modes of transmission, and a growing understanding of the ways it can affect people who have the infection, there is much left to learn.
There are a host of possible direct and indirect effects of SARS-Co-V2 on the nervous system. One of the early symptoms of infection can be a loss of the sense of smell or taste. In fact, in at least one animal model, the virus can be traced spreading from the nose into the brain where it can affect respiratory centers, possibly contributing to some of the disease’s effects on breathing. Yet, there is only limited evidence of brain damage directly caused by the virus. Its impact on the nervous system may also be related to the infection’s effects on the immune system, blood clotting, and other consequences of severe illness.
Neurological effects, nonetheless, are common. One study of patients with COVID-19 found 42% had neurologic symptoms at disease onset and 82% had some neurological effects at some point during the disease, ranging from mild to severe. Whether a direct or indirect effect, some of the more common neurologic issues occurring during the acute infection include painful muscles, headache, dizziness and loss of smell or taste. Some of the more serious are impaired thinking or wakefulness, strokes, and seizures. There can also be longer-term consequences of COVID-19 including problems with memory and thinking, deficits related to stroke, and secondary diseases such as Guillain–Barré syndrome (rapid onset of muscle weakness caused by the immune system damaging the nerves in the legs, arms or even face). There, however, have been few high-quality long-term studies of patients who have had COVID-19 that would allow us to know how frequently these and other potential neurologic symptoms occur or last.
As in other areas of medicine, the best treatment is prevention. Wear an effective mask covering both the mouth and the nose, consider eye protection in closed spaces, wash hands frequently, and maintain social distancing.
The University of Kentucky is increasingly the first choice for students, faculty and staff to pursue their passions and their professional goals. In the last two years, Forbes has named UK among the best employers for diversity, and INSIGHT into Diversity recognized us as a Diversity Champion four years running. UK is ranked among the top 30 campuses in the nation for LGBTQ* inclusion and safety. UK has been judged a “Great College to Work for" three years in a row, and UK is among only 22 universities in the country on Forbes' list of "America's Best Employers." We are ranked among the top 10 percent of public institutions for research expenditures — a tangible symbol of our breadth and depth as a university focused on discovery that changes lives and communities. And our patients know and appreciate the fact that UK HealthCare has been named the state’s top hospital for five straight years. Accolades and honors are great. But they are more important for what they represent: the idea that creating a community of belonging and commitment to excellence is how we honor our mission to be not simply the University of Kentucky, but the University for Kentucky.